HC Wainwright Issues Pessimistic Forecast for RYTM Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Equities research analysts at HC Wainwright decreased their Q1 2025 earnings estimates for shares of Rhythm Pharmaceuticals in a research note issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.74) per share for the quarter, down from their previous estimate of ($0.68). HC Wainwright has a "Buy" rating and a $70.00 price objective on the stock. The consensus estimate for Rhythm Pharmaceuticals' current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals' Q2 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.87) EPS and Q1 2026 earnings at ($0.60) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). The business had revenue of $41.83 million during the quarter, compared to analyst estimates of $38.48 million. Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%.

Other equities analysts have also issued reports about the stock. The Goldman Sachs Group lifted their target price on shares of Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the company a "buy" rating in a report on Thursday, December 5th. Oppenheimer began coverage on shares of Rhythm Pharmaceuticals in a research report on Friday, December 20th. They issued an "outperform" rating and a $76.00 price objective for the company. Jefferies Financial Group began coverage on Rhythm Pharmaceuticals in a research report on Thursday, January 2nd. They set a "buy" rating and a $80.00 target price on the stock. Morgan Stanley reiterated an "overweight" rating and set a $72.00 price target on shares of Rhythm Pharmaceuticals in a research report on Friday, March 7th. Finally, Canaccord Genuity Group raised their price objective on Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the company a "buy" rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, Rhythm Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $69.46.

Remove Ads

Rhythm Pharmaceuticals Stock Performance

Rhythm Pharmaceuticals stock traded up $1.31 during midday trading on Wednesday, hitting $54.80. 416,136 shares of the company were exchanged, compared to its average volume of 509,820. Rhythm Pharmaceuticals has a fifty-two week low of $35.17 and a fifty-two week high of $68.58. The firm has a market capitalization of $3.46 billion, a PE ratio of -12.66 and a beta of 2.30. The business has a fifty day simple moving average of $55.25 and a two-hundred day simple moving average of $55.07.

Insider Buying and Selling

In related news, EVP Yann Mazabraud sold 75,000 shares of the firm's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the transaction, the executive vice president now owns 40,370 shares of the company's stock, valued at $2,078,247.60. This trade represents a 65.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Christopher Paul German sold 635 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total value of $36,334.70. Following the completion of the transaction, the chief accounting officer now directly owns 2,070 shares in the company, valued at approximately $118,445.40. The trade was a 23.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 108,131 shares of company stock worth $5,781,098 in the last ninety days. 5.60% of the stock is owned by corporate insiders.

Institutional Trading of Rhythm Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. FMR LLC grew its holdings in shares of Rhythm Pharmaceuticals by 79.7% in the 3rd quarter. FMR LLC now owns 50,295 shares of the company's stock worth $2,635,000 after acquiring an additional 22,306 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Rhythm Pharmaceuticals by 307.1% in the third quarter. BNP Paribas Financial Markets now owns 14,425 shares of the company's stock valued at $756,000 after acquiring an additional 10,882 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Rhythm Pharmaceuticals by 241.9% during the third quarter. Principal Financial Group Inc. now owns 32,586 shares of the company's stock valued at $1,707,000 after acquiring an additional 23,054 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Rhythm Pharmaceuticals during the 3rd quarter worth about $649,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Rhythm Pharmaceuticals by 1.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,866 shares of the company's stock valued at $22,730,000 after purchasing an additional 5,908 shares in the last quarter.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.